[go: up one dir, main page]

WO1998038985A3 - Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases - Google Patents

Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases Download PDF

Info

Publication number
WO1998038985A3
WO1998038985A3 PCT/EP1998/001240 EP9801240W WO9838985A3 WO 1998038985 A3 WO1998038985 A3 WO 1998038985A3 EP 9801240 W EP9801240 W EP 9801240W WO 9838985 A3 WO9838985 A3 WO 9838985A3
Authority
WO
WIPO (PCT)
Prior art keywords
carvedilol
preventive
medicament
inflammatory diseases
therapeutic treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1998/001240
Other languages
French (fr)
Other versions
WO1998038985A2 (en
Inventor
Akira Matsumori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Priority to AU69203/98A priority Critical patent/AU6920398A/en
Publication of WO1998038985A2 publication Critical patent/WO1998038985A2/en
Publication of WO1998038985A3 publication Critical patent/WO1998038985A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Medicament for preventive and therapeutic treatment of inflammatory diseases which comprises as an active ingredient a substance selected from the group consisting of carvedilol, optically active isomers thereof, its hydroxy-carbazole derivatives and pharmacologically acceptable salts thereof.
PCT/EP1998/001240 1997-03-06 1998-03-05 Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases Ceased WO1998038985A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU69203/98A AU6920398A (en) 1997-03-06 1998-03-05 Medicament for preventive and therapeutic treatment of inflammatory diseas es

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP97/51473 1997-03-06
JP9051473A JPH10251147A (en) 1997-03-06 1997-03-06 Preventing and/or treating agent for inflammatory disease

Publications (2)

Publication Number Publication Date
WO1998038985A2 WO1998038985A2 (en) 1998-09-11
WO1998038985A3 true WO1998038985A3 (en) 1998-12-23

Family

ID=12887931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/001240 Ceased WO1998038985A2 (en) 1997-03-06 1998-03-05 Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases

Country Status (3)

Country Link
JP (1) JPH10251147A (en)
AU (1) AU6920398A (en)
WO (1) WO1998038985A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024198A1 (en) * 2000-09-21 2002-03-28 University Of Houston Novel therapy
EP1684764A2 (en) 2003-10-09 2006-08-02 Inverseon, Inc. Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012178A1 (en) * 1992-12-01 1994-06-09 Smithkline Beecham Corporation Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012178A1 (en) * 1992-12-01 1994-06-09 Smithkline Beecham Corporation Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GIORA Z. FEUERSTEIN ET AL.: "Carvedilol: Preclinical profile and rationale for its use in hypertension, coronary syndromes, and congestive haert failure", CARDIOVASCULAR REVIEWS & REPORTS, vol. 17, no. 10, 1996, pages 27 - 38, XP002072749 *
GIORA.Z.FEUERSTEIN ET AL.: "Carvedilol update III: Rationale for use in congestive heart failure", DRUGS OF TODAY, vol. 31, no. suppl. F, 1995, pages 1 - 23, XP002072748 *
PETER LIU ET AL.: "Viral myocarditis: Balance between viral infection and immune response", CAN.J.CARDIOL., vol. 12, no. 10, 1996, pages 935 - 943, XP002072747 *
VINCENT R. ZALES ET AL.: "Endocarditis, pericarditis and myocarditis", PEDIATRIC ANNALS, vol. 26, no. 2, February 1997 (1997-02-01), pages 116 - 121, XP002072750 *

Also Published As

Publication number Publication date
AU6920398A (en) 1998-09-22
JPH10251147A (en) 1998-09-22
WO1998038985A2 (en) 1998-09-11

Similar Documents

Publication Publication Date Title
NZ514574A (en) Novel method of treatment
AU3990797A (en) Sustained release formulation
NO971206D0 (en) Prolonged-frigjöringsformulering
NO20022014D0 (en) Controlled release of hydrocodone formulations
ITMI961152A0 (en) THERAPEUTIC COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF AN ACTIVE INGREDIENT, ESTROGEN OR PROGESTIN OR MIXTURES THEREOF
AU3153097A (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
UY26372A1 (en) "IMIDAZO-3-IL-AMINAS BICÍCLICAS PROCEDURE FOR ITS PREPARATION AND DRUGS THAT CONTAIN THEM"
ES2088312T3 (en) CONTROLLED RELEASE FORMULATION CONTAINING TRAMADOL.
WO2003015779A3 (en) Matrix controlled transdermal therapeutic system for the use of pramipexole and ropinirole
CA2382387A1 (en) Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
WO1999004772A3 (en) Use of levobupivacaine
NO994165L (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, travel sickness and dizziness
AU1495595A (en) Sustained-release dosage forms of alfuzosin hydrochloride
CA2253130A1 (en) A medicament for treating obesity and improving lipid metabolism
MXPA02002452A (en) Preventive and therapeutic agents for eye diseases.
EP1666041A3 (en) Xanthine derivatives for treating neurodegenerative disorders
WO2003005967A3 (en) Dual release levodopa ethyl ester and decarboxylase in controlled release core
EP1440691A3 (en) Treatment of neurotic disorders
AR023687A1 (en) A COMPOSITION FOR THE TREATMENT OF EXTERNAL RETINA DISORDERS AND THE USE OF A GLUTAMATE ANTAGONIST FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF EXTERNAL RETINA DISORDERS
AU2001258395A1 (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
ES2109752T3 (en) MEDICATION FOR THERAPEUTIC AND PROPHYLACTIC TREATMENT OF DISEASES CAUSED BY HYPERPLASIA OF THE SMOOTH MUSCLE CELLS.
PT1150704E (en) MELAGATRAN FOR THE TREATMENT OF INFLAMMATION
WO2001030331A3 (en) Therapeutic compositions including protein kinase c inhibitors
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998538161

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase